Lynx1 Capital Management LP
Lynx1 Capital Management LP's purchase track record
How the stock did after each of Lynx1 Capital Management LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/6/2026 | KRRO | $79K | pending | pending | — |
| 6/25/2026 | PASG | $206K | +15.5% | pending | — |
| 3/31/2026 | KRRO | $6K | +16.4% | -15.6% | +17.5% |
| 12/19/2025 | TCRX | $146K | +16.1% | -3.5% | +9.3% |
| 10/28/2025 | CGEM | $1.39M | +45.4% | +50.9% | +3.6% |
| 10/21/2025 | NEUP | $3.28M | -16.9% | +0.4% | +4.9% |
| 10/16/2025 | CGEM | $1.58M | +22.0% | +68.7% | +6.2% |
| 10/8/2025 | CGEM | $10.35M | +69.6% | +131.9% | +0.4% |
| 9/11/2025 | PASG | $224K | +53.2% | +16.2% | +1.3% |
| 7/22/2025 | PASG | $734K | +54.3% | +125.2% | +7.7% |
| 5/19/2025 | TCRX | $3.11M | +44.4% | -21.8% | +11.9% |
| 12/27/2024 | PASG | $241K | -42.0% | -49.6% | +3.4% |
| 12/12/2024 | TCRX | $386K | -40.7% | -46.7% | -0.1% |
| 11/25/2024 | PASG | $285K | -16.6% | -42.4% | -1.1% |
| 11/15/2024 | TCRX | $4K | -53.5% | -71.9% | +1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Scancell Secures Debt Financing for Phase 3 Trials. Scancell, a subsidiary of Neuphoria Therapeutics, has completed up to US$25 million in debt financing. This funding provides additional options to support the Phase 3 development of iSCIB1+. The capital helps finance clinical trials, which is a key step in the company's development pipeline.
Transaction History
| KRRO | ▲ Buy | Open Market | 1,462 | $19K | 8/10/2026 | View on chart |
| KRRO | ▲ Buy | Open Market | 5,222 | $60K | 8/6/2026 | View on chart |
| PASG | ▲ Buy | Open Market | 50,055 | $206K | 6/25/2026 | View on chart |
| KRRO | ▲ Buy | Open Market | 520 | $6K | 3/31/2026 | View on chart |
| TCRX | ▲ Buy | Open Market | 6,232 | $6K | 12/23/2025 | View on chart |
| TCRX | ▲ Buy | Open Market | 75,500 | $68K | 12/22/2025 | View on chart |
| TCRX | ▲ Buy | Open Market | 80,069 | $72K | 12/19/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 165,667 | $1.4M | 10/28/2025 | View on chart |
| NEUP | ▲ Buy | Open Market | 639,110 | $3.3M | 10/21/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 32,217 | $253K | 10/17/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 150,000 | $1.3M | 10/16/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 51,500 | $409K | 10/15/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 15,032 | $114K | 10/14/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 277,298 | $2.0M | 10/10/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 626,043 | $4.2M | 10/9/2025 | View on chart |
| CGEM | ▲ Buy | Open Market | 556,300 | $3.6M | 10/8/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 11,900 | $83K | 9/15/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 19,783 | $138K | 9/12/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 325 | $2K | 9/11/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 66,423 | $379K | 7/24/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 49,302 | $283K | 7/23/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 13,123 | $71K | 7/22/2025 | View on chart |
| TCRX | ▲ Buy | Open Market | 1,200,000 | $1.4M | 5/20/2025 | View on chart |
| TCRX | ▲ Buy | Open Market | 1,388,794 | $1.7M | 5/19/2025 | View on chart |
| PASG | ▲ Buy | Open Market | 373,645 | $241K | 12/27/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 100,000 | $290K | 12/13/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 31,800 | $96K | 12/12/2024 | View on chart |
| PASG | ▲ Buy | Open Market | 29,300 | $20K | 11/27/2024 | View on chart |
| PASG | ▲ Buy | Open Market | 167,055 | $118K | 11/26/2024 | View on chart |
| PASG | ▲ Buy | Open Market | 259,998 | $147K | 11/25/2024 | View on chart |
| TCRX | ▲ Buy | Open Market | 947 | $4K | 11/15/2024 | View on chart |
| TCRX | ▼ Sell | Open Market | 10,000 | $25K | 5/31/2023 | View on chart |
| TCRX | ▼ Sell | Open Market | 15,000 | $38K | 5/31/2023 | View on chart |
| TCRX | ▼ Sell | Open Market | 400 | $1K | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.